/ANIP
ANIP Stock - ANI Pharmaceuticals, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$82.85+0.02%
+$0.02 (+0.02%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.54
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).67
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+8.6%upside
Target: $89.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANIP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$82.02 – $83.68
TARGET (TP)$90.00
STOP LOSS$76.22
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$99.50
52W Low$52.74
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $614.38M | $486.82M | $316.38M | $216.14M | $208.47M |
| Gross Profit | $364.17M | $305.30M | $177.60M | $115.53M | $121.32M |
| Gross Margin | 59.3% | 62.7% | 56.1% | 53.5% | 58.2% |
| Operating Income | $584,000 | $46.97M | $-35,283,000 | $-39,793,000 | $-16,016,000 |
| Net Income | $-18,522,000 | $18.78M | $-47,896,000 | $-42,603,000 | $-22,548,000 |
| Net Margin | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% |
| EPS | $-1.04 | $0.95 | $-3.05 | $-3.40 | $-1.88 |
Company Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$73
Average Target
↓ 12.2% Downside
Now
$50
Low
$73
Average
$85
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | H.C. Wainwright | Initiation | Buy | $84 |
| March 14th 2025 | Jefferies | Initiation | Buy | $80 |
| March 12th 2025 | JP Morgan | Initiation | Overweight | $85 |
| December 11th 2024 | Leerink Partners | Initiation | Outperform | $80 |
| October 11th 2024 | Piper Sandler | Initiation | Overweight | $68 |
| March 15th 2024 | CapitalOne | Initiation | Overweight | $80 |
| August 22nd 2023 | H.C. Wainwright | Reiterated | Buy | $73← $60 |
| March 1st 2023 | Guggenheim | Initiation | Buy | $55 |
| September 7th 2022 | H.C. Wainwright | Initiation | Buy | $50 |
Earnings History & Surprises
ANIPBeat Rate
89%
Last 18 quarters
Avg Surprise
+20.6%
EPS vs Estimate
Beats / Misses
16/2
Last 12 quarters
Latest EPS
$2.04
Q4 2025
EPS Surprise History
Q1 24
+25.0%
$1.00vs$0.80
Q2 24
+23.5%
$1.21vs$0.98
Q3 24
+9.7%
$1.02vs$0.93
Q4 24
+22.9%
$1.34vs$1.09
Q1 25
+15.6%
$1.63vs$1.41
Q2 25
+24.1%
$1.70vs$1.37
Q3 25
+30.4%
$1.80vs$1.38
Q4 25
+17.2%
$2.04vs$1.74
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $2.02 | — | — | — |
Q4 2025 | Nov 7, 2025 | $1.74 | $2.04 | +17.2% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $1.38 | $1.80 | +30.4% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $1.37 | $1.70 | +24.1% | ✓ BEAT |
Q1 2025 | Feb 28, 2025 | $1.41 | $1.63 | +15.6% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $1.09 | $1.34 | +22.9% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.93 | $1.02 | +9.7% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $0.98 | $1.21 | +23.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.80 | $1.00 | +25.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.76 | $1.27 | +67.1% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $0.64 | $1.28 | +100.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $0.34 | $1.17 | +244.1% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $0.68 | $0.76 | +11.8% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $0.58 | $0.64 | +10.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $0.12 | $0.13 | +8.3% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.08 | $-0.12 | -250.0% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $0.82 | $0.54 | -34.1% | ✗ MISS |
Q4 2021 | Nov 1, 2021 | $0.71 | $1.01 | +42.3% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $0.65 | $0.67 | +3.1% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $100
📈 PositiveBenzinga•Dec 9, 2025, 03:27 PM•Also:
ANI Pharma Elects Thomas Haughey As Chairman Of The Board, Succeeding Patrick Walsh
➖ NeutralBenzinga•Dec 1, 2025, 11:53 AM
Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $115
📈 PositiveBenzinga•Nov 10, 2025, 02:47 PM
ANI Pharmaceuticals Raises FY2025 Adj EPS Guidance from $6.98-$7.35 to $7.37-$7.64 vs $7.28 Est; Raises FY2025 Sales Guidance from $818.000M-$843.000M to $854.000M-$873.000M vs $844.680M Est
📈 PositiveBenzinga•Nov 7, 2025, 11:54 AM
ANI Pharmaceuticals Q3 Adj. EPS $2.04 Beats $1.75 Estimate, Sales $227.813M Beat $211.041M Estimate
📈 PositiveBenzinga•Nov 7, 2025, 11:51 AM
ANI Pharma To Highlight Results From NEW DAY Clinical Trial Of ILUVIEN 0.19 Mg For Use In DME Patients In Late-Breaking Oral Presentation During Retina Subspecialty Day 2025 At AAO Meeting
📈 PositiveBenzinga•Oct 16, 2025, 10:54 AM
Truist Securities Maintains Hold on ANI Pharmaceuticals, Raises Price Target to $90
➖ NeutralBenzinga•Oct 9, 2025, 02:41 PM
JP Morgan Maintains Overweight on ANI Pharmaceuticals, Raises Price Target to $115
📈 PositiveBenzinga•Sep 24, 2025, 12:23 PM•Also:
HC Wainwright & Co. Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121
📈 PositiveBenzinga•Sep 17, 2025, 02:36 PM
Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $114
📈 PositiveBenzinga•Sep 8, 2025, 01:43 PM
Frequently Asked Questions about ANIP
What is ANIP's current stock price?
ANI Pharmaceuticals, Inc. (ANIP) is currently trading at $82.85 per share. The stock has moved +0.02% today.
What is the analyst price target for ANIP?
The average analyst price target for ANIP is $90.00, based on 1 analyst.
What sector is ANI Pharmaceuticals, Inc. in?
ANI Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ANIP's market cap?
ANI Pharmaceuticals, Inc. has a market capitalization of $1.86 billion, making it a small-cap company.
Does ANIP pay dividends?
No, ANI Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARSUF
Fagron N.V.
$23.50
Mkt Cap: $1.7B
BGM
BGM Group Ltd.
$4.36
Mkt Cap: $0.9B
CASBF
CanSino Biologics Inc.
$4.28
Mkt Cap: $1.5B
DMPHF
Dermapharm Holding SE
$39.56
Mkt Cap: $2.1B
GTBIF
Green Thumb Industries Inc.
$8.15
Mkt Cap: $1.9B
HROW
Harrow Health, Inc.
$46.40
Mkt Cap: $1.7B
HTSUF
Hisamitsu Pharmaceutical Co., Inc.
$29.00
Mkt Cap: $2.1B
TCNNF
Trulieve Cannabis Corp.
$8.53
Mkt Cap: $1.6B
TLRY
Tilray Brands, Inc.
$11.16
Mkt Cap: $1.2B
TSMRF
Tsumura & Co.
$23.20
Mkt Cap: $1.7B
Explore stocks similar to ANIP for comparison